Fused ring heteroaryl compounds and their use as Trk inhibitors
US9701681B2 · kind B2 · utility
30Cited by
0References
19Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Dec 14, 2015 |
| Grant date | Jul 11, 2017 |
| Priority date | — |
| Expiry date | Dec 14, 2035 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P37/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The disclosure provides novel chemical compounds represented by Formula I or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof. The compounds can be used as an inhibitor of Trk and are useful in the treatment of pain, cancer, inflammation, neurodegenerative disease and certain infectious diseases.In some compounds of Formula I, Q is —CH═CR3C(O)NR4R5, —C≡CC(O)NR4R5, or
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.